In a significant stride for urological health, Rigicon Inc.
proudly announces groundbreaking enhancements to its ContiReflex®
artificial urinary sphincter and Testi10 testicular prosthesis.
These state-of-the-art developments, recently showcased at the
American Urological Association meeting and featured in the
International Journal of Impotence Research, mark a pioneering leap
in medical technology. With the latest ContiReflex® model, Rigicon
introduces a novel dual-bladder system, designed to offer unmatched
control and comfort for patients suffering from male stress
incontinence. Meanwhile, the Testi10 testicular prosthesis sets a
new standard in prosthetic reliability and patient safety,
achieving a remarkable 99.8% survival rate over 54 months.
Rigicon's commitment to innovation and patient care continues to
redefine industry standards and improve the quality of life for
patients globally.
RONKONKOMA, N.Y., May 12, 2024
/PRNewswire-PRWeb/ -- Rigicon Inc., a pioneering medical device
company, today announced significant advancements in its
ContiReflex® artificial urinary sphincter and Testi10TM testicular
prosthesis lines, showcased in recent high-profile scientific
forums.
Presenting our findings at the AUA meeting
and publishing in a respected journal are testaments to the
scientific validity and potential impact of our products.
ContiReflex®: Innovations in Managing Male Incontinence
The new generation ContiReflex® artificial urinary sphincter
introduces a dual-bladder system in its pressure regulating balloon
(PRB) to effectively manage male stress incontinence, particularly
following radical prostatectomy. This technology was recently
detailed in a paper presented at the prestigious American
Urological Association (AUA) meeting, signaling a major leap
forward in patient care.
Key Enhancements and Clinical Data:
- Precision Cuff Sizing: The device's cuffs range from 3.5 to 5
cm, adjustable in 0.25 cm increments, allowing for precise
customization to patient anatomy.
- Surgical Technique Improvements: Predominantly using a
two-incision method, the device has shown promising early safety
outcomes in a study involving 50 patients.
- Strong Safety Profile: Early findings revealed minimal
complications, with a notable 98% device survival rate at 18
months, as reported in the study.
Testi10: Setting New Standards in Testicular Prosthetics
Rigicon's Testi10 testicular prosthesis has been recognized for
its exceptional reliability and safety in a comprehensive study
published in the International Journal of Impotence Research. The
study, involving 427 patients, demonstrated a survival rate of
99.8% over 54 months, affirming the prosthesis's superior design
and performance.
Device Features and Performance Insights:
- Model Variety: The Testi10 is available in multiple models,
including saline-filled and solid silicone, to suit diverse patient
needs.
- Impressive Reliability: With a very low revision rate and no
significant complications, the device underscores Rigicon's
commitment to quality and safety.
A Dedication to Clinical Excellence and Patient Outcomes:
"These significant milestones, achieved through rigorous
research and peer-reviewed by the global medical community,
underscore our commitment to innovation and excellence in patient
care," said Professor Steven K Wilson, Global Medical Director at
Rigicon. "Presenting our findings at the AUA meeting and publishing
in a respected journal are testaments to the scientific validity
and potential impact of our products."
Rigicon remains at the forefront of urological health, driving
advancements that redefine treatment standards and improve patient
lives worldwide.
Media Contact
Savas Karaoglu, Rigicon Inc, 1
8882029790, operations@rigicon.com, www.rigicon.com
View original content to download
multimedia:https://www.prweb.com/releases/rigicon-announces-groundbreaking-advances-in-prosthetic-urology-with-contireflex-and-testi10-testicular-prosthesis-302142872.html
SOURCE Rigicon Inc